Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15586614 | 0.89 | EPHX2 (0.63) | HTTALDH1A1LMNAEPHX2MAOA | |
| SCHEMBL25889043 | 0.84 | HDAC1 (0.53) | HTTALDH1A1LMNAEPHX2HPGD | |
| SCHEMBL9918334 | 0.81 | NOX1 (0.38) | HTTALDH1A1LMNAEPHX2HPGD | |
| SCHEMBL434490 | 0.78 | EPHX2 (0.77) | HTTALDH1A1LMNAEPHX2MAOA | |
| SCHEMBL11383890 | 0.78 | ALDH1A1 (0.48) | HTTALDH1A1LMNAEPHX2MAOA | |
| SCHEMBL10509516 | 0.75 | HTT (0.59) | HTTALDH1A1LMNAEPHX2MAOA | |
| SCHEMBL7454625 | 0.75 | HTT (0.59) | HTTALDH1A1LMNAEPHX2MAOA | |
| SCHEMBL30199790 | 0.75 | HTT (0.59) | HTTALDH1A1LMNAEPHX2MAOA | |
| SCHEMBL3601956 | 0.75 | HTT (0.59) | HTTALDH1A1LMNAEPHX2MAOA | |
| SCHEMBL1332876 | 0.75 | HTT (0.59) | HTTALDH1A1LMNAEPHX2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052597-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | CADILA HEALTHCARE LIMITED (IN) | 2021-02-25 | — | — | US | disclosed |
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | Bugworks Research, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10543223-B2 | Mannose derivatives useful for treating pathologies associated with adherent E. coli | ENTEROME (FR) | 2020-01-28 | — | — | US | disclosed |
| US-20190292199-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | Bugworks Research, Inc. | 2019-09-26 | — | — | US | disclosed |
| WO-2019145919-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | CADILA HEALTHCARE LIMITED (IN) | 2019-08-01 | — | — | WO | disclosed |
| WO-2017021549-A1 | MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI | ENTEROME (FR) | 2017-02-09 | — | — | WO | disclosed |
| EP-2699572-B1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-20120165322-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | HTT 4733/4885ALDH1A1 1632/4885LMNA 4792/4885 |
| US-20190292199-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | ALPI, UROD, HLA-C | HTT 574/4885ALDH1A1 1285/4885LMNA 1549/4885 |
| US-10543223-B2 | Mannose derivatives useful for treating pathologies associated with adherent E. coli | FPR3, CCR3, RXFP3 | HTT 4282/4885ALDH1A1 2484/4885LMNA 4182/4885 |
| US-20120165322-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | HTT 2577/4885ALDH1A1 2674/4885LMNA 1872/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | HTT 4142/4885ALDH1A1 1507/4885LMNA 4638/4885 |
| US-20210052597-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | ABCB11, DHPS, MRPL21 | HTT 3609/4885ALDH1A1 171/4885LMNA 4636/4885 |
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | ALPI, HLA-A, HLA-B | HTT 2061/4885ALDH1A1 568/4885LMNA 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.